FGFR2c peptide

Description

Antigenic peptide of fibroblast growth factor receptor 2c mesenchymal splice variant

See full description

Catalogue number crb1200371
Antibody Anti-FGFR2c antibody
Antigen Peptide FGFR2c peptide
Aliases Fibroblast growth factor receptor 2c, FGFR2c
Cross-Reactivity Human
Storage -20°C
References

Pfaff, M., Xue, K., Li, L., Horowitz, M., Steinbacher, D. and Eswarakumar, J. (2016). FGFR2c-mediated ERK–MAPK activity regulates coronal suture development. Dev Biol, 415(2), 242-250. PMID: 27034231

 

Ranieri, D., Rosato, B., Nanni, M., Belleudi, F. and Torrisi, M. (2017). Expression of the FGFR2c mesenchymal splicing variant in human keratinocytes inhibits differentiation and promotes invasion. Mol Carcinog, 57(2), 272-283. PMID: 29068468

Specificity Protein
The fibroblast growth factor receptor (FGFR) family consists of four transmembrane receptor tyrosine kinases (FGFR1‐4), which regulate important physiological processes, such as cell proliferation, differentiation, migration and survival throughout the body. FGFR2c is known as the mesenchymal FGFR2 isoform and when aberrantly expressed in epithelial cells it induces epithelial‐mesenchymal transition (EMT) and is involved in cancer progression.

FGFR2 signalling is critical for proper craniofacial development. A gain-of-function mutation in the 2c splice variant is associated with Crouzon syndrome, which is characterized by craniosynostosis, the premature fusion of one or more of the cranial vault sutures, leading to craniofacial maldevelopment. FGFR2c-mediated ERK-MAPK signalling is a key mediator of craniofacial growth and coronal suture development.

FGFR2c peptide

Cat No. Pack Size Price Qty

crb1200371e

50ug

$112.50